| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 43...
MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today anno...
MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today anno...